FRACTURE RISK AND ZOLEDRONIC ACID THERAPY IN MEN WITH OSTEOPOROSIS

THE NEW ENGLAND JOURNAL OF MEDICINE • NOV. 2012

EFFECTS OF TERIPARATIDE COMPARED WITH RISEDRONATE ON THE RISK OF FRACTURES IN SUBGROUPS OF POSTMENOPAUSAL WOMEN WITH SEVERE OSTEOPOROSIS: THE VERO TRIAL.

JOURNAL OF BONE AND MINERAL RESEARCH, VOL. 33 • 2018

EFFECTS OF TERIPARATIDE AND RISEDRONATE ON NEW FRACTURES IN POST-MENOPAUSAL WOMEN WITH SEVERE OSTEOPOROSIS (VERO): A MULTICENTRE, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED CONTROLLED TRIAL

LANCET; 391: 230–40, PUBLISHED ONLINE • JAN. 2018

THE EFFECT OF TERIPARATIDE COMPARED WITH RISEDRONATE ON REDUCTION OF BACK PAIN IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROTIC VERTEBRAL FRACTURES

INTERNATIONAL OSTEOPOROSIS FOUNDATION AND NATIONAL OSTEOPOROSIS FOUNDATION 2011 • 2011

BONE MINERAL DENSITY RESPONSE RATES ARE GREATER IN PATIENTS TREATED WITH ABALOPARATIDE COMPARED WITH THOSE TREATED WITH PLACEBO OR TERIPARATIDE: RESULTS FROM THE ACTIVE PHASE 3 TRIAL

ELSEVIER BONE 120: 137 - 140 • OUT. 2018

A IMPORTÂNCIA DA PESQUISA CLÍNICA PARA O BRASIL

INTERFARMA - JULHO 2019

DETERMINAR O VALOR DE 25OH D EM UMA POPULAÇÃO DE MULHERES PÓS-MENOPÁUSICAS COM MAIS DE 60 ANOS COM OSTEOPENIA E OSTEOPOROSE E A CORRELAÇÃO COM PARÂMETROS DO METABOLISMO ÓSSEO E FRATURAS VERTEBRAIS.

FUNDAÇÃO OSVALDO CRUZ – IFF • OUTUBRO 2006

IS IT ETHICAL TO USE PLACEBOS IN OSTEOPOROSIS TRIALS?

JOURNAL OF CLINICAL DENSITOMETRY, VOL. 9, NO. 3, 274E280 • 2006

POSTMENOPAUSAL OSTEOPOROSIS

THE NEW ENGLAND JORNAL OF MEDICINE, 353:595-603 • 2005

PERFIL DE SUJEITOS DE PESQUISA CLÍNICA EM UM CENTRO AMBULATORIAL INDEPENDENTE

CIÊNCIA & SAÚDE COLETIVA, 13(3) • 2008

SAFETY AND TOLERABILITY OF BAZEDOXIFENE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM A 3-YEAR, RANDOMIZED, PLACEBO- AND ACTIVE-CONTROLLED CLINICAL TRIAL

ASBMR MEETING • 2007

ASSOCIATION OF BACK PAIN WITH HYPOVITAMINOSIS D IN POSTMENOPAUSAL WOMEN WITH LOW BONE MASS

BMC MUSCULOSKELETAL DISORDERS, 14:184 • 2013

DENOSUMAB ADMINISTRATION IS NOT ASSOCIATED WITH FRACTURE HEALING COMPLICATIONS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FREEDOM TRIAL

ASBMR 32ND ANNUAL MEETING, TORONTO, ONTARIO • OCTOBER 15–19, 2010

CONCENTRAÇÃO PLASMÁTICA DE 25 HIDROXIVITAMINA D EM MULHERES NA PÓS-MENOPAUSA COM BAIXA DENSIDADE MINERAL ÓSSEA

ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA • DEZEMBRO 2009

EFFECT OF DENOSUMAB ON FRACTURE HEALING IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FREEDOM TRIAL

EUROPEAN SYMPOSIUM ON CALCIFIED TISSUES 37TH CONGRESS, GLASGOW, UK • JUNE 26 –30, 2010

GLUCOCORTICOID-INDUCED OSTEOPOROSIS

ARQUIVOS BRASILEIROS ENDOCRINOLOGIA E METABOLOGIA, VOL 50 Nº 4 • AGOSTO 2006

EFFECT OF DENOSUMAB VS ALENDRONATE ON BONE TURNOVER MARKERS AND BONE MINERAL DENSITY CHANGES AT 12 MONTHS BASED ON BASELINE BONE TURNOVER LEVEL

THE JOURNAL OF RHEUMATOLOGY, 36:11 • 2009

COMPARISON OF THE EFFECT OF DENOSUMAB AND ALENDRONATE ON BMD AND BIOCHEMICAL MARKERS OF BONE TURNOVER IN POSTMENOPAUSAL WOMEN WITH LOW BONE MASS: A RANDOMIZED, BLINDED, PHASE 3 TRIAL

JOURNAL OF BONE AND MINERAL RESEARCH, VOLUME 24, NUMBER 1 • 2009

PERCENTAGE OF WOMEN ACHIEVING NON-OSTEOPOROTIC BMD T-SCORES AT THE SPINE AND HIP OVER 8 YEARS OF DENOSUMAB TREATMENT

JOURNAL OF BONE AND MINERAL RESEARCH, VOLUME 24, NUMBER 1 • 2009

RELATIONSHIP BETWEEN BONE MINERAL DENSITY T‐SCORE AND NONVERTEBRAL FRACTURE RISK OVER 10 YEARS OF DENOSUMAB TREATMENT

JOURNAL OF BONE AND MINERAL RESEARCH, VOL. 34, NO. 6, P. 1033–1040 • 2019

FREEDOM TRIAL: DENOSUMAB IS NOT ASSOCIATED WITH FRACTURE HEALING COMPLICATIONS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

OSTEOPOROSIS INT 22 (SUPPL 1):S119–S408 • 2011

PERCENTAGE OF WOMEN ACHIEVING NON-OSTEOPOROTIC BMD T-SCORES AT THE LUMBAR SPINE (LS) AND TOTAL HIP (TH) DURING UP TO 8 YEARS OF DENOSUMAB (DMAB) TREATMENT

OSTEOPOROSIS INT  26 (SUPPL 1):S71–S380 • 2015

RELATIONSHIP BETWEEN TOTAL HIP BMD T-SCORE AND INCIDENCE OF NONVERTEBRAL FRACTURE WITH UP TO 10 YEARS OF DENOSUMAB (DMAB) TREATMENT

OSTEOPOROSIS INT 27 (SUPPL 1):S39–S62 • 2016